The Latest Breaking News from Mustang Bio

Mustang Bio Stock Jumps 180% After FDA Grants Orphan Drug Status to Brain Cancer Drug

Mustang Bio stock surged over 180% on Monday after the FDA granted its brain cancer drug candidate an orphan drug designation.

International Business Times UK · Jul 8, 2025

Mustang Bio (MBIO) Stock Explodes 260% After FDA Grants Key Cancer Drug Designation

Mustang Bio Inc (NASDAQ:MBIO) shares are trading sharply higher Monday afternoon. The company earlier saw a positive development as the FDA granted Orphan Drug Designation to its cell therapy candidate, MB-101. Here’s what investors need to know.

Benzinga · Jul 7, 2025

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193  in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Benzinga · Jul 27, 2022